이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC

2026년 6월 1일 업데이트: Xiongjun Ye, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

A Study on the Safety and Efficacy of Atorvastatin in Combination With Axitinib and Toripalimab for Advanced Renal Cell Carcinoma Guided by Drug Sensitivity Testing Using Patient-Derived Tumor Cell Models

Given the significant challenge of drug resistance in patients with advanced renal cell carcinoma (RCC) despite standard treatment, this study aims to translate preclinical findings into clinical practice, preliminarily evaluating the safety, tolerability, and preliminary efficacy of atorvastatin calcium combined with targeted and immunotherapy in patients with advanced RCC. We hypothesize that for some patients with advanced RCC who do not respond well to targeted + immunotherapy, identifying potential beneficiaries based on their PTC susceptibility testing and combining atorvastatin with these treatments in real-world settings could be an effective susceptibility enhancement strategy, thereby further improving patient survival. This prospective clinical study aims to validate the safety and efficacy of this "organoid-guided precision combination therapy model."

연구 개요

상세 설명

1. Study Objectives

1.1 Primary Objective: To evaluate the effectiveness of personalized treatment strategies guided by patient-derived tumor cell cluster (PTC) susceptibility testing in patients with advanced/metastatic renal cell carcinoma. The primary endpoint is objective response rate (ORR). Specifically, this study compares the in vitro drug sensitivity differences between two treatment regimens: "targeted therapy + immunotherapy" and "targeted therapy + immunotherapy + atorvastatin calcium tablets," by performing PTC culture and susceptibility testing on tumor tissue obtained from patient biopsies. This will guide subsequent clinical treatment decisions regarding the addition of oral atorvastatin calcium tablets to standard targeted therapy combined with immunotherapy.

1.2 Secondary Objectives:

  1. To evaluate the disease control rate, progression-free survival, overall survival, 12-month progression-free survival rate, and 12- and 24-month overall survival rates of atorvastatin combined with targeted and immunotherapy regimens in patients with advanced/metastatic renal cell carcinoma.
  2. Safety: Incidence of adverse events and serious adverse reactions.
  3. To evaluate health-related quality of life (HRQoL).

2. Study Design

2.1 Overall Design This is a single-center, prospective, non-randomized controlled, two-arm clinical trial of superiority. The study plans to enroll 20-40 patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC). All subjects will receive targeted therapy plus immunotherapy. The addition of oral atorvastatin will be determined based on the drug sensitivity results of the patient-derived tumor cell cluster (PTC) model. Treatment will continue until any of the following occurs: disease progression, intolerable toxicity, the subject voluntarily requests to discontinue treatment or withdraw from the study, or other reasons determined by the investigator necessitate discontinuation of treatment and withdrawal from the study.

This study consists of three phases: screening, treatment (visit), and follow-up. All subjects must meet the inclusion and exclusion criteria. The screening period will not exceed 28 days. After passing the screening examination and evaluation, subjects will enter the treatment period. The treatment period consists of 21-day cycles, during which subjects must receive treatment and undergo regular visits as specified in the protocol.

Safety follow-up begins on day 30 (±7 days) from the start of the last study treatment, with participants required to undergo evaluation at the research center. Following the safety follow-up period, participants will enter a 2-year survival follow-up period, with follow-ups conducted at the end of every two treatment cycles. Follow-ups can be conducted via telephone or other effective methods, primarily collecting information on participant survival status and subsequent anti-tumor treatment. For participants without radiographic evidence of disease progression, imaging examinations will continue at the established efficacy assessment frequency until disease progression, death, loss to follow-up, withdrawal of informed consent, initiation of other anti-tumor treatments, or investigator termination of the study.

2.2 Study Endpoints

  1. Primary endpoint: Objective response rate (ORR);
  2. Secondary endpoints: Progression-free survival (PFS), overall survival (OS), disease control rate (DCR), 12-month progression-free survival rate (PFS rate), 12-month overall survival rate (OS rate), 24-month overall survival rate (OS rate), safety, and health-related quality of life (HRQoL).

2.3 Study Location and Duration

This study is planned to be conducted at a single center from April 2026 to April 2030, with the Cancer Hospital of the Chinese Academy of Medical Sciences as the main center. It is expected to enroll 20-40 patients with advanced or metastatic clear cell renal cell carcinoma.

2.4 Study Drugs

  1. Axitinib (Inritar)

    Dosage Form: Tablets

    Strength: 5mg/tablet

    Dosage: Oral

    The initial dose is 5mg twice daily, and the dose can be gradually adjusted according to patient tolerance.

  2. Toripalimab Injection (Tuoyi)

    Dosage Form: Injection

    Strength: 80mg/2ml

    Dosage: Intravenous Infusion

    Administer intravenously every 3 weeks at a dose of 240mg, continuously until disease progression or adverse reactions occur.

  3. Atorvastatin Calcium Tablets (Lipitor)

Dosage Form: Tablets

Strength: 10mg/tablet

Dosage: Oral

The initial dose is 10mg once daily, which can be gradually adjusted according to patient tolerance.

2.5 PTC Construction Procedure

This study used a patient-derived tumor cell cluster (PTC) model to assess drug sensitivity. The specific procedure included:

  1. Collecting tumor tissue samples from patients with advanced renal cell carcinoma and culturing them in vitro in the laboratory.
  2. Promoting the formation of tumor-like organoids by tumor cells under specific culture conditions, maintaining their biological characteristics in vitro.
  3. Performing drug sensitivity testing to evaluate two drug combinations: targeted therapy combined with immunotherapy (axitinib + toripalimab) or targeted therapy combined with immunotherapy and atorvastatin calcium tablets (axitinib + toripalimab + atorvastatin).
  4. Evaluating the inhibitory effect of different drug combinations on tumor cells in the PTC model by exposing them to different drug combinations, and deciding whether to provide combination therapy to patients based on the drug sensitivity results.

연구 유형

중재적

등록 (추정된)

40

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Chaoyang District
      • Beijing, Chaoyang District, 중국, 100021
        • Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing 101205
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Voluntarily agree to participate in the study and be willing and able to sign the informed consent form.
  2. Histologically confirmed clear cell renal cell carcinoma.
  3. Advanced renal cell carcinoma not suitable for curative surgery or radiotherapy, or metastatic renal cell carcinoma, AJCC stage IV.
  4. No prior systemic therapy for renal cell carcinoma, except for prior adjuvant or neoadjuvant therapy for completely resectable renal cell carcinoma, provided that the therapy did not include agents targeting VEGF or VEGFR and recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy.
  5. At least one measurable lesion according to RECIST version 1.1.
  6. Karnofsky Performance Status score ≥70.
  7. Estimated life expectancy of more than 3 months.
  8. Aged 18 to 75 years.
  9. Adequate major organ function and hematologic function, including:

    • Absolute neutrophil count ≥1500 cells/μL without granulocyte colony-stimulating factor support within 2 weeks before Cycle 1 Day 1.
    • Platelet count ≥80 × 10^9/L.
    • White blood cell count ≥2500/μL and ≤15000/μL without G-CSF support.
    • Lymphocyte count ≥500/μL.
    • Hemoglobin ≥9.0 g/dL, without erythropoietin dependence and without packed red blood cell transfusion within the previous 2 weeks.
    • ALT, AST, and alkaline phosphatase ≤3 × upper limit of normal; ≤5 × upper limit of normal is allowed for liver metastases. For participants with bone metastases, alkaline phosphatase ≤5 × upper limit of normal is allowed.
    • Total bilirubin ≤1.5 × upper limit of normal. Participants with known Gilbert syndrome may be enrolled if total bilirubin is ≤3 × upper limit of normal.
    • Serum albumin ≥2.8 g/dL.
    • Serum creatinine ≤2.0 × upper limit of normal or calculated creatinine clearance ≥30 mL/min.
    • Urine protein-to-creatinine ratio ≤1 mg/mg, equivalent to ≤113.2 mg/mmol.
  10. Female participants who are not postmenopausal or surgically sterile must agree to use two adequate contraceptive methods, including at least one method with an annual failure rate of less than 1%.
  11. Sexually active participants of reproductive potential and their partners must agree to use medically accepted contraceptive methods during the study and for 5 months after the last dose for female participants and 7 months after the last dose for male participants.
  12. Female participants of childbearing potential must not be pregnant at screen

Exclusion Criteria:

  1. Prior systemic therapy for renal cell carcinoma, unless the investigator can provide evidence that the participant was assigned to a placebo group.
  2. Known central nervous system metastases.
  3. Active malignancy within the past 24 months, except for renal cell carcinoma, definitively treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix or bladder. Participants with a history of localized low-risk prostate cancer may be eligible if they received curative treatment and have had no prostate-specific antigen recurrence within the past 5 years.
  4. Radiotherapy within 21 days before initiation of study treatment, except palliative radiotherapy for bone lesions completed at least 2 weeks before study treatment.
  5. Participation in another clinical study or receipt of an investigational drug within 4 weeks before initiation of study treatment.
  6. Receipt of a live vaccine within 30 days before planned initiation of study treatment.
  7. Proteinuria >1+ on urine dipstick. Participants with urine protein ≥1 g/24 hours on 24-hour urine collection are not eligible.
  8. Fasting total cholesterol >300 mg/dL, equivalent to 7.75 mmol/L, and/or fasting triglycerides >2.5 × upper limit of normal.
  9. Uncontrolled diabetes mellitus, defined as fasting blood glucose >1.5 × upper limit of normal. Participants may be enrolled after glucose-lowering treatment if adequately controlled.
  10. Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued bisphosphonate or denosumab therapy.
  11. QTc interval >480 ms.
  12. Inadequate recovery from toxicity or complications caused by major surgery before treatment initiation.
  13. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that may affect absorption of study drugs.
  14. Clinically significant hematuria, hematemesis, or hemoptysis of more than 0.5 teaspoon, approximately 2.5 mL, of red blood within 12 weeks before the first dose, or any other significant bleeding history.
  15. Significant cardiovascular impairment within 12 months before the first dose, including New York Heart Association class II or higher congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accident, or hemodynamically unstable arrhythmia. Participants with left ventricular ejection fraction below the institutional lower limit of normal are also excluded.
  16. Active infection requiring systemic treatment.
  17. Positive human immunodeficiency virus test.
  18. Active hepatitis B or hepatitis C infection.
  19. Known history or evidence of interstitial lung disease.
  20. History of non-infectious pneumonitis requiring steroids or current pneumonitis.
  21. Diagnosis of immunodeficiency or receipt of chronic systemic steroid therapy or other immunosuppressive therapy within 7 days before the first dose. Physiologic corticosteroid doses up to prednisone 10 mg/day or equivalent are permitted.
  22. Active autoimmune disease requiring systemic treatment within the past 2 years, except psoriasis. Replacement therapy, such as thyroxine, insulin, or physiologic corticosteroid replacement therapy, is not considered systemic treatment.
  23. Breastfeeding or pregnancy at screening or baseline.
  24. Female participants of childbearing potential who do not agree to use highly effective contraception during the study and for 120 days after study termination.
  25. Male participants who have not undergone successful vasectomy and do not agree to use condoms with spermicide from the first dose until 120 days after the last dose, unless abstinent.
  26. Known intolerance to any study drug or any excipient.
  27. Prior allogeneic tissue or solid organ transplantation.
  28. Participants requiring analgesics must be on a stable analgesic regimen at study entry.
  29. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage once monthly or more frequently.
  30. Uncontrolled hypertension, defined as persistent systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg.
  31. Inability to swallow tablets or capsules.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Axitinib + Toripalimab
Participants will receive axitinib 5 mg orally twice daily and toripalimab 240 mg intravenously every 3 weeks as standard targeted therapy combined with immunotherapy.
Axitinib 5 mg orally twice daily.
Toripalimab 240 mg intravenously every 3 weeks.
실험적: Atorvastatin + Axitinib + Toripalimab
Participants will receive axitinib 5 mg orally twice daily, toripalimab 240 mg intravenously every 3 weeks, and atorvastatin calcium 10 mg orally once daily based on patient-derived tumor-like cell cluster drug sensitivity testing.
Axitinib 5 mg orally twice daily.
Toripalimab 240 mg intravenously every 3 weeks.
Atorvastatin calcium 10 mg orally once daily, administered based on patient-derived tumor-like cell cluster drug sensitivity testing.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Objective Response Rate (ORR)
기간: From baseline until disease progression, death, withdrawal, or end of treatment, assessed up to 24 months.
ORR is defined as the proportion of participants who achieve complete response (CR) or partial response (PR) according to RECIST version 1.1.
From baseline until disease progression, death, withdrawal, or end of treatment, assessed up to 24 months.

2차 결과 측정

결과 측정
측정값 설명
기간
Progression-Free Survival (PFS)
기간: From treatment initiation until disease progression or death, assessed up to 24 months.
PFS is defined as the time from treatment initiation to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.
From treatment initiation until disease progression or death, assessed up to 24 months.
Overall Survival (OS)
기간: From treatment initiation until death from any cause, assessed up to 48 months.
OS is defined as the time from treatment initiation to death from any cause.
From treatment initiation until death from any cause, assessed up to 48 months.
Disease Control Rate (DCR)
기간: From baseline until disease progression, assessed up to 24 months.
DCR is defined as the proportion of participants who achieve complete response, partial response, or stable disease according to RECIST version 1.1.
From baseline until disease progression, assessed up to 24 months.
12-Month Progression-Free Survival Rate
기간: 12 months after treatment initiation.
The proportion of participants who remain alive without disease progression at 12 months after treatment initiation.
12 months after treatment initiation.
12-Month Overall Survival Rate
기간: 12 months after treatment initiation.
The proportion of participants who remain alive at 12 months after treatment initiation.
12 months after treatment initiation.
24-Month Overall Survival Rate
기간: 24 months after treatment initiation.
The proportion of participants who remain alive at 24 months after treatment initiation.
24 months after treatment initiation.
Incidence of Adverse Events
기간: From treatment initiation to 30 days after the last dose of study treatment.
Safety will be assessed by the incidence and severity of adverse events and serious adverse events graded according to NCI-CTCAE version 5.0.
From treatment initiation to 30 days after the last dose of study treatment.
Health-Related Quality of Life (HRQoL)
기간: From baseline through treatment and follow-up, assessed up to 24 months.
HRQoL will be assessed using the EORTC QLQ-C30 questionnaire.
From baseline through treatment and follow-up, assessed up to 24 months.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 5월 14일

기본 완료 (추정된)

2028년 3월 1일

연구 완료 (추정된)

2030년 4월 1일

연구 등록 날짜

최초 제출

2026년 6월 1일

QC 기준을 충족하는 최초 제출

2026년 6월 1일

처음 게시됨 (실제)

2026년 6월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 6월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 6월 1일

마지막으로 확인됨

2026년 5월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다